Slide 1: Q1 2024 Results Conference Call and Webcast
Q1 2024 Results Conference Call and Webcast May 2, 2024 Nasdaq: ZYME | zymeworks.com
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation and the accompanying oral commentary include “forward-looking statements” or information within the meaning of the applicable securities legislation, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchan
Slide 3: Q1 Earnings Results Call Agenda
Q1 Earnings Results Call Agenda Ken Galbraith Paul Moore, Ph.D. Bijal Desai, MBA Chair and CEO CSO VP, Finance & Strategy • Financial Update • R&D Update • Q&A • Q&A • Q&A Making a Meaningful Difference 3
Slide 4: Ken Galbraith
Ken Galbraith Chair & CEO Making a Meaningful Difference 4
Slide 5: Key Developments for 2024 and Expected News Flow
Key Developments for 2024 and Expected News Flow • Our partner Jazz completed the U.S. regulatory submission for • Pivotal Phase 3 top-line data readout in GEA 1L targeted by zanidatamab seeking accelerated approval in 2L BTC our partner Jazz in late 2024 • Jazz initiated a Phase 3 global confirmato
Slide 6: Q1 2024 Financial Results
Q1 2024 Financial Results • Revenue decreased in Q1 2024 primarily due to lower In millions USD Q1 2024 Q1 2023 development support payments from Jazz and lower revenue from our partners for research support and $10.0 $35.6 other payments compared to Q1 2023. Revenue • R&D Expense decreased primaril
Slide 7: Projected Cash Runway Supports R&D Priorities into 2H 2027
Projected Cash Runway Supports R&D Priorities into 2H 2027 Current Financial Status: Potential sources to extend cash runway beyond 2H 2027: • Cash resources1 of approx. $420.5M • Additional regulatory approval and commercial milestones for zanidatamab from Jazz and BeiGene (as of March 31, 2024) •
Slide 8: Paul Moore, Ph.D.
Paul Moore, Ph.D. Chief Scientific Officer Making a Meaningful Difference 8
Slide 9: Zymeworks Trispecific Co-Stimulatory TCE: Overcoming Lack of Efficacy and Durability of Responses
Zymeworks Trispecific Co-Stimulatory TCE: Overcoming Lack of Efficacy and Durability of Responses in Solid Tumors by Optimization of Signal 1 and 2 Low T cell infiltration and T cell anergy remain Zymeworks Trispecific Co-Stimulatory Program challenges in the treatment of solid tumors Provides Signa
Slide 10: TriTCE Co-Stim: A Next Generation Trispecific T Cell Engager Platform
TriTCE Co-Stim: A Next Generation Trispecific T Cell Engager Platform • Designed to enhance T cell activity and provide more durable anti-tumor control • CLDN 18.2 used as a model tumor antigen and activity benchmarked against clinical stage bispecifc TCEs Sustained T cell Cytotoxicity and T cell Fi
Slide 11: DLL3 TriTCE Co-Stim: A Next Generation Trispecific T Cell Engager
DLL3 TriTCE Co-Stim: A Next Generation Trispecific T Cell Engager • Designed to incorporate CD28 co-stimulation to improve activity beyond conventional DLL3 x CD3 bispecifics by enhancing T cell activity and providing more durable responses in poorly infiltrated ‘cold’ tumors Enhanced T Cell Cytotox
Slide 12: TriTCE Co-Stim: Differentiated Co-Stimulatory (CD28) Platform vs. Clinical Competitors
TriTCE Co-Stim: Differentiated Co-Stimulatory (CD28) Platform vs. Clinical Competitors Co-Stimulatory (CD28) Zymeworks’ Potential Advantage and Limitations of Alternative Strategies TCE Strategies ✓ Zymeworks TriTCE Co-Stim provides balanced CD3 and CD28 activation to prevent overactivation of T cel
Slide 13: ZW191: Key Design Considerations; On Track for Clinical Studies in 2024
ZW191: Key Design Considerations; On Track for Clinical Studies in 2024 ZW191’s Novel mAb Drives Superior Internalization, Anti-Tumor Activity Across Multiple Tumor Types Payload Delivery, and Tissue Penetration And Range of FRα Expression (PDX models) IGROV-1 Internalization Intracellular Payload P
Slide 14: ZW191: Novel and Proprietary TOPO1i Payload Well-Tolerated
ZW191: Novel and Proprietary TOPO1i Payload Well-Tolerated ZW191 Shows a Compelling Tolerability Profile of 60 mg/kg in NHP 1 • No mortality or body weight effects Dose Clinical Hematology & Adverse Clinical observations Histopathology HNSTD mg/kg Chemistry coagulation effects • No ophthalmic effect
Slide 15: Milestone Opportunities in 2024 & 2025
Milestone Opportunities in 2024 & 2025 Several opportunities for business Cash resources* as of development with unencumbered March 31, 2024 $420.5M global rights for novel compounds Multiple value generating Current cash runway projected to opportunities expected in 2024 and support development goa
Slide 16: Q&A
Q&A Ken Galbraith Chair & CEO Paul Moore, Ph.D. CSO Bijal Desai, MBA VP, Finance & Strategy Making a Meaningful Difference 16